Dr. Laura K. Aguilar joined Candel in 2006 and has served as the company’s Chief Medical Officer since 2014. She is a physician specializing in Pediatric Hematology Oncology with a research doctorate in Immunology. She has more than 20 years of experience in laboratory research, clinical translation in immunotherapy and gene transfer, and clinical cancer research. Dr. Aguilar’s professional focus and interest are in the development of novel therapeutics to improve the outcome for cancer patients.
In her role, Dr. Aguilar develops clinical trial strategies and oversees clinical trial activities to move the company forward in research and development. As chief clinical lead, she works with physicians, regulatory authorities and business partners, builds and maintains key opinion leader relationships, and advises clinical teams at study sites.
Prior to joining Candel, Dr. Aguilar was an attending physician in Pediatric Oncology at Dana Farber Cancer Institute and Children’s Hospital in Boston. She also served as associate director and clinical liaison for the Harvard Gene Therapy Initiative.
Dr. Aguilar has an undergraduate degree in Biochemistry from the University of California at Davis, and an M.D. and Ph.D. in Immunology from Baylor College of Medicine in Houston. She completed her Pediatric residency and a Pediatric Hematology Oncology fellowship at Texas Children’s Hospital in Houston.